Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXT STEP trial in untreated CLL/SLL
NL-OMON52647Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, ibrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by HOVON. Primary endpoint: Bone marrow uMRD complete remission after intensification. Started Dec 2020; status: recruiting.
02
Drugs
venetoclaxibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON52647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52647.